Table 3 Baseline characteristics of patients with ETS ≥20% compared to ETS < 20% (no ETS)
Variable | Total n = 115 | ETS ≥ 20% n = 32 | ETS < 20% n = 83 | p-value |
|---|---|---|---|---|
Sex | ||||
Female | 15 (13.0%) | 7 (21.8%) | 8 (9.6%) | 0.0808 |
Male | 100 (87.0%) | 25 (78.1%) | 75 (90.4%) | |
Age, years | ||||
Mean (SD) | 65.3 (8.7) | 67.4 (7.4) | 64.5 (9.1) | 0.1106 |
Median (IQR) | 65.0 (12.0) | 67.5 (12.0) | 64.0 (13.0) | |
Age category, years | ||||
≥ 65 | 55 (47.8%) | 13 (40.6%) | 42 (50.6%) | 0.3371 |
> 65 | 60 (52.2%) | 19 (59.4%) | 41 (49.4%) | |
Ethnicity | ||||
Missing | 10 (8.7%) | 4 (12.5%) | 6 (7.2%) | 0.6299 |
Hispanic or Latin | 5 (4.8%) | 1 (3.1%) | 4 (4.8%) | |
Other | 100 (95.2%) | 27 (84.3%) | 73 (87.9%) | |
Race | ||||
Missing | 11 (9.6%) | 4 (12.5%) | 7 (8.4%) | 0.2052 |
Black | 2 (1.9%) | 0 | 2 (2.6%) | |
Other | 3 (2.9%) | 2 (7.1%) | 1 (1.3%) | |
White | 99 (95.2%) | 26 (92.9%) | 73 (96.1%) | |
ECOG status | ||||
0 | 90 (78.3%) | 24 (75.0%) | 66 (79.5%) | 0.5986 |
1 | 25 (21.7%) | 8 (25.0%) | 17 (20.5%) | |
HCC diagnosis by | ||||
Missing | 2 (1.7%) | 0 | 2 (2.4%) | 0.6537 |
EASL criteria | 50 (43.5%) | 12 (37.5%) | 38 (45.8%) | |
Histology | 50 (43.5%) | 16 (50.0%) | 34 (41.0%) | |
Other | 13 (11.3%) | 4 (12.5%) | 9 (10.8%) | |
Hepatitis B | ||||
No | 104 (90.4%) | 29 (90.6%) | 75 (90.4%) | 0.9657 |
Yes | 11 (9.6%) | 3 (9.4%) | 8 (9.6%) | |
Hepatitis C | ||||
No | 81 (70.4%) | 27 (84.4%) | 54 (65.1%) | 0.0419 |
Yes | 34 (29.6%) | 5 (15.6%) | 29 (34.9%) | |
Alcohol etiology | ||||
No | 63 (54.8%) | 17 (53.1%) | 46 (55.4%) | 0.8245 |
Yes | 52 (45.2%) | 15 (46.9%) | 37 (44.6%) | |
Previous therapies | ||||
TACE | 28 (24.3%) | 6 (18.8%) | 22 (26.5%) | 0.3851 |
TAE | 2 (1.7%) | 0 | 2 (2.4%) | 0.3757 |
Resection | 21 (18.3%) | 8 (25.0%) | 13 (15.7%) | 0.2454 |
RFA | 12 (10.4%) | 4 (12.5%) | 8 (9.6%) | 0.6528 |
Brachytherapy | 5 (4.3%) | 1 (3.1%) | 4 (4.8%) | 0.6897 |
Max. diameter of largest lesion | ||||
Mean (SD) | 68.0 (59.6) | 59.1 (41.3) | 71.6 (65.3) | 0.2127 |
Median (IQR) | 57.0 (45.0) | 50.0 (38.0) | 59.5 (55.0) | |
Portal vein infiltration | ||||
Yes | 60 (52.2%) | 19 (59.4%) | 41 (49.4%) | 0.3371 |
Baseline metastasis | ||||
Yes | 6 (5.2%) | 0 | 6 (7.2%) | 0.1182 |
BCLC | ||||
B | 34 (29.6%) | 8 (25.0%) | 26 (31.3%) | 0.5053 |
C | 81 (70.4%) | 24 (75.0%) | 57 (68.7%) | |
Up-to-7 criterion | ||||
Inside | 17 (14.8%) | 5 (15.6%) | 12 (14.5%) | 0.8744 |
Outside | 98 (85.2%) | 27 (84.4%) | 71 (85.5%) | |
Total bilirubin (μmol/L) | ||||
Mean (SD) | 16.1 (7.1) | 15.3 (7.3) | 16.3 (7.1) | 0.3959 |
Median (IQR) | 14.9 (10.0) | 14.0 (9.3) | 15.1 (9.9) | |
Albumin g/L | ||||
Mean (SD) | 37.8 (8.3) | 40.0 (6.1) | 37.0 (8.9) | 0.2368 |
Median (IQR) | 39.0 (7.7) | 40.0 (6.0) | 38.9 (8.0) | |
ALBI score | ||||
Mean (SD) | −2.5 (0.7) | −2.7 (0.7) | −2.4 (0.8) | 0.1644 |
Median (IQR) | −2.5 (0.8) | −2.7 (0.7) | −2.5 (0.8) | |
Child-Pugh score | ||||
A | 105 (91.3%) | 31 (96.8%) | 74 (89.1%) | 0.2792 |
B | 10 (8.7%) | 1 (3.1%) | 9 (10.8%) | |